FDA Approves Amneal’s Sodium Oxybate Oral Solution

Amneal Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for sodium oxybate oral solution 500 mg/mL, a generic version of Jazz Pharmaceuticals’ Xyrem. This approval marks a significant milestone for the company as it expands its portfolio into the sleep disorder treatment space.

Sodium oxybate is a central nervous system depressant used to treat cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy, a chronic neurological disorder affecting roughly 150,000 Americans. It is widely considered a standard-of-care therapy due to its ability to consolidate sleep and reduce cataplexy episodes.

Amneal had previously been distributing an authorized generic version of sodium oxybate in limited quantities. With full FDA approval, the company is now poised to offer a more widely available and cost-effective alternative in a market previously dominated by a single manufacturer.

“This approval expands Amneal’s Affordable Medicines portfolio into a critical therapy area for patients living with narcolepsy,” said Tony Rosa, Senior Vice President of Retail Affordable Medicines at Amneal. “We’re proud to bring more affordable access to a medicine that plays a vital role in improving quality of life for people with this rare condition.”

Common side effects of sodium oxybate include nausea, dizziness, vomiting, somnolence, bedwetting, and tremor in adults. In pediatric patients, additional side effects may include headache, decreased appetite, weight loss, and sleepwalking.

With this approval, Amneal continues to broaden its footprint in complex generics, aiming to offer high-quality, lower-cost alternatives in underserved therapeutic areas.